%20will%20reduce%20hepatic%20fat%20in%20nonalcoholic%20fatty%20liver%20disease%20(NAFLD)%20patients.%20%0AJournal%0AMolecular%20Systems%20Biology%0AKey%20O...){kind=link}
Nicotinamide Riboside Supplementation with Metabolic Cofactors Reduces Liver Fat in NAFLD Patients: Clinical Findings
Objectives
To determine if combined metabolic activator supplementation (CMA) will reduce hepatic fat in nonalcoholic fatty liver disease (NAFLD) patients.
Journal
Molecular Systems Biology
Key Outcomes
- CMA significantly decreased liver fat by 10%, and improved liver function, as seen through the significant reductions in serum alanine aminotransferase, ALT (39%), aspartate aminotransferase, AST (30%), and uric acid (12%) levels.
- CMA reduced plasma levels of inflammatory proteins, suggesting a decrease in liver inflammation.
- Fecal and salivatory sample analyses showed that CMA supplementation caused beneficial changes in the microbiome.
Duration
10 weeks
Dose
2000 mg*
*One dose of 1 g NR, 3.73 g L-carnitine tartrate, 12.35 g serine, and 2.55 g N-acetyl-L-cysteine for the first 14 days and two doses for the next 56 days.
Study Design
Randomized, single-blind, placebo-controlled, phase II study in 31 patients with nonalcoholic fatty liver disease (NAFLD)